Overview

Pilot Evaluation of Atomoxetine on Attention Deficit Hyperactivity Disorder (ADHD) Symptoms in Adolescents With Cannabis abusE

Status:
Terminated

Trial end date:
2009-06-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether atomoxetine is effective in reducing ADHD (Attention Deficit/Hyperactivity Disorder) symptoms in adolescents with ADHD and comorbid cannabis abuse.

Phase:

Phase 4

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Atomoxetine Hydrochloride